NCT07481526 A Prospecitve Multicenter, Observational Registry Study
| NCT ID | NCT07481526 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Chronic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2026-02-27 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2026-02-27 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Eligibility Criteria
Inclusion Criteria: * Male or female patients aged ≥18 years. * Willing and able to provide written informed consent to participate in the study. * Confirmed CKD diagnosis at enrolment, defined by at least one of the following: * eGFR \<60 mL/min/1.73 m² for ≥3 months, OR * Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months Exclusion Criteria: * Having a life-threatening comorbidity with life expectancy \< 2 years. * Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months. * Pregnant or breastfeeding women. * Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment. * Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
Contact & Investigator
Xiao Qiang Ding
PRINCIPAL INVESTIGATOR
Zhongshan Hospital Affiliated with Fudan University
Frequently Asked Questions
Who can join the NCT07481526 clinical trial?
This trial is open to participants of all sexes, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07481526 currently recruiting?
Yes, NCT07481526 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07481526 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07481526 clinical trial?
NCT07481526 is sponsored by AstraZeneca. The principal investigator is Xiao Qiang Ding at Zhongshan Hospital Affiliated with Fudan University. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.